logo
logo

Accent Therapeutics Announce $75m Series C Financing

Feb 07, 2024•over 1 year ago

Amount Raised

$75 Million

LexingtonBiotechnology

Investors

Timefolio Capital (Formerly Known As Ns Investment)The Mark Foundation For Cancer ResearchAbb Vie VenturesEco R1 CapitalGvDroia VenturesAtlas VentureThe Column GroupJohnson & Johnson Innovation – Jjdc, Inc.Bristol Myers SquibbMirae Asset Capital Life Science

Description

Accent Therapeutics announced the closing of a $75 million Series C financing. The financing was led by Mirae Asset Capital Life Science, with participation from other new investors, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc. as well as all existing investors. Naveen Krishnan, MD, MPhil, Managing Director of Mirae Asset Capital Life Science will join the company’s Board of Directors.

Company Information

Company

Accent Therapeutics

Location

Lexington, Massachusetts, United States

About

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech